| RS2143664797 |
GNAO1
|
Health Risk |
Pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2143664808 |
GNAO1
|
Health Risk |
Pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2143664859 |
GNAO1
|
Health Risk |
Pathogenic |
— |
| RS2143664861 |
GNAO1
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 17 |
| RS2143664881 |
GNAO1
|
Health Risk |
Likely pathogenic |
Developmental and epileptic encephalopathy, 17 |
| RS2143665312 |
GNAO1
|
Health Risk |
Pathogenic |
Neurodevelopmental disorder with involuntary movements, Neurodevelopmental disorder with involuntary movements |
| RS2143669286 |
STX1B
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143669495 |
STX1B
|
Health Risk |
Likely pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143670048 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2143670119 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143670560 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143670786 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143670818 |
STX1B
|
Health Risk |
Likely pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143670891 |
STX1B
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143671037 |
STX1B
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, Generalized epilepsy with febrile seizures plus |
| RS2143671063 |
STX1B
|
Health Risk |
Likely pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143671466 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143671563 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143671676 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672004 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672014 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672030 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672087 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672139 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672195 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672296 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672313 |
MED13
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder 61, Intellectual developmental disorder 61 |
| RS2143672476 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672609 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143672833 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143673063 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143673258 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia complementation group O, Hereditary cancer |
| RS2143673772 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143674103 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143674150 |
NF1
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Cardiovascular phenotype |
| RS2143676047 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2143676048 |
CNTNAP1
|
Health Risk |
Likely pathogenic |
Congenital hypomyelination neuropathy with or without arthrogryposis, Congenital hypomyelination neuropathy with or without arthrogryposis |
| RS2143677013 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group A |
| RS2143677258 |
RAD51C
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2143677288 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2143677351 |
STX1B
|
Health Risk |
Pathogenic/Likely pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143677612 |
STX1B
|
Health Risk |
Likely pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143677618 |
STX1B
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143677745 |
STX1B
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143678134 |
MED13
|
Health Risk |
Likely pathogenic |
— |
| RS2143678941 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143679153 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2143679565 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia complementation group O, Hereditary cancer-predisposing syndrome |
| RS2143679715 |
PIEZO2
|
Health Risk |
Likely pathogenic |
— |
| RS2143680554 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143680611 |
JUP
|
Health Risk |
Pathogenic |
Naxos disease, Arrhythmogenic right ventricular dysplasia 12 |
| RS2143682648 |
PLCG2
|
Health Risk |
Likely pathogenic |
Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation, Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation |
| RS2143683612 |
JUP
|
Health Risk |
Pathogenic |
Naxos disease, Arrhythmogenic right ventricular dysplasia 12 |
| RS2143687619 |
MED13
|
Health Risk |
Pathogenic |
Intellectual developmental disorder 61, Intellectual developmental disorder 61 |
| RS2143688328 |
PSMD12
|
Health Risk |
Pathogenic |
Stankiewicz-Isidor syndrome, Stankiewicz-Isidor syndrome |
| RS2143692659 |
ELAC2
|
Health Risk |
Likely pathogenic |
Combined oxidative phosphorylation defect type 17, Combined oxidative phosphorylation defect type 17 |
| RS2143697976 |
JUP
|
Health Risk |
Pathogenic |
Naxos disease, Arrhythmogenic right ventricular dysplasia 12 |
| RS2143699590 |
GNAO1
|
Health Risk |
Pathogenic |
— |
| RS2143699618 |
GNAO1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurodevelopmental disorder with involuntary movements, Developmental and epileptic encephalopathy |
| RS2143699686 |
GNAO1
|
Health Risk |
Pathogenic |
Neurodevelopmental disorder with involuntary movements, Developmental and epileptic encephalopathy |
| RS2143699701 |
GNAO1
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder with involuntary movements, Developmental and epileptic encephalopathy |
| RS2143699753 |
GNAO1
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder with involuntary movements, Neurodevelopmental disorder with involuntary movements |
| RS2143704776 |
GNAO1
|
Health Risk |
Conflicting classifications of pathogenicity |
Seizure, Seizure |
| RS2143705016 |
GNAO1
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Early-infantile DEE |
| RS2143705059 |
GNAO1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurodevelopmental disorder with involuntary movements, Early-infantile DEE |
| RS2143705605 |
PLCG2
|
Health Risk |
Likely pathogenic |
Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation, Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation |
| RS2143706752 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143707089 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143707235 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143707493 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2143707605 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143707713 |
NF1
|
Health Risk |
Pathogenic |
— |
| RS2143707737 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143707749 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143707759 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143708010 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143708173 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2143710613 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143711335 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2143711627 |
FANCA
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2143711687 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143717943 |
RAD51C
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2143719799 |
PPM1D
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder with gastrointestinal difficulties and high pain threshold, Intellectual developmental disorder with gastrointestinal difficulties and high pain threshold |
| RS2143719857 |
PPM1D
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder with gastrointestinal difficulties and high pain threshold, Intellectual developmental disorder with gastrointestinal difficulties and high pain threshold |
| RS2143720302 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2143721294 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Hereditary cancer-predisposing syndrome |
| RS2143723668 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia complementation group O, Hereditary cancer-predisposing syndrome |
| RS2143724113 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143724329 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143724700 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2143724764 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2143724912 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2143725868 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2143726485 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2143727680 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2143729488 |
SMCHD1
|
Health Risk |
Likely pathogenic |
— |
| RS2143730785 |
PPM1D
|
Health Risk |
Pathogenic |
Neurodevelopmental delay, Neurodevelopmental delay |
| RS2143730896 |
PPM1D
|
Health Risk |
Likely pathogenic |
— |
| RS2143731129 |
PPM1D
|
Health Risk |
Pathogenic |
Autosomal dominant non-syndromic intellectual disability, Autosomal dominant non-syndromic intellectual disability |
| RS2143731708 |
TBX2
|
Health Risk |
Conflicting classifications of pathogenicity |
Vertebral anomalies and variable endocrine and T-cell dysfunction, TBX2-related disorder |